February 20, 2026
Poland’s medical market sits at an unusual intersection: a nationally centralized drug reimbursement system that is being actively redesigned, and a patient access pathway for medical cannabis that has largely remained out-of-pocket. In 2025, Poland’s Ministry of Health signaled a broad reform agenda for the reimbursement framework (Refundacja), including procedural streamlining and new mechanisms that could materially change how products are “invited” into reimbursement and how applicants disclose pricing and use data.
For medical cannabis manufacturers, importers, and distributors, this matters even if reimbursement is not immediately expanded—because reimbursement law and practice often set the expectations for evidence, utilization monitoring, supply continuity, and price governance across the market.
This article is informational only and not legal advice.
Poland’s reimbursement system is governed primarily by the Reimbursement Act and implemented through periodic announcements (obwieszczenia) that publish the official lists of reimbursed medicines and other products. These announcements are posted on the Ministry of Health’s official website.
External reporting in 2025 described a wide package of draft amendments to reimbursement laws and procedures, including changes intended to speed access, adjust negotiation mechanics, and introduce new planning and “call” mechanisms where the Minister can prompt a company to submit a reimbursement application when patient need requires it.
Even before any reform takes effect, Poland’s reimbursement system remains highly structured and timetable-driven. The Ministry of Health publishes the reimbursed list announcements on gov.pl, including mid-year and quarterly effective dates.
External link (official): https://www.gov.pl/web/zdrowie/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych
For businesses, this cadence affects:
One of the most closely watched concepts in the 2025 reform discussions is the Ministry of Health’s ability to call for reimbursement applications (in practice, a form of targeted invitation). While details depend on the final legal text and implementing regulations, the direction of travel is clear: Poland wants more proactive tools to address unmet need and accelerate access.
For the medical cannabis category, this could create a pathway—directly or indirectly—for structured evaluation of specific products, dosage forms, or patient groups, particularly if policymakers decide to test pilots or carve-outs.
Poland has allowed medical cannabis since 2017 in a model that relies heavily on pharmacy-compounded magistral preparations made from imported pharmaceutical raw material. In practice, patient affordability and prescribing behavior are shaped by:
Industry coverage and market commentary reported a sharp drop in prescriptions following tighter controls on telemedicine prescribing, with figures cited such as a decrease from 68,000 prescriptions in October 2024 to 28,000 in December 2024.
External link: https://internationalcbc.com/medical-cannabis-prescriptions-are-decreasing-in-poland/
Even if prescription volumes later stabilize, that reported decline is a signal for manufacturers and importers: policy changes can quickly alter demand, which in turn affects supply planning, working capital, and batch-level import economics.
Poland’s system recognizes a targeted import pathway for products without a Polish marketing authorization, used for individual patient needs. AOTMiT (the Agency for Health Technology Assessment and Tariff System) provides an English-language explainer of “import for individual needs,” which helps illustrate how this mechanism is understood in the broader health system.
External link (official): https://www.aotm.gov.pl/en/medicines/import-for-individual-needs/
Separately, reputable legal and industry summaries of Poland’s reimbursement framework note that reimbursement may also cover products imported through targeted import procedures—under defined conditions.
For medical cannabis operators, targeted import is not necessarily the primary commercial model (the market has developed through pharmacy supply chains and raw material import permissions). But targeted import can become relevant in several scenarios:
If reimbursement reform strengthens “invitation” mechanisms and requires more transparent dossiers, targeted import could become a more formalized “bridge” tool—particularly if the Ministry seeks controlled access programs while evaluating broader reimbursement implications.
The most practical impact of reimbursement reform for businesses is often price governance, not only “whether reimbursement exists.” Even if medical cannabis is not widely reimbursed, the reimbursement framework can influence price expectations and market negotiations.
Your research notes point to consultations that may require dossiers to disclose more detail about:
The strategic implication: companies should expect less tolerance for thin evidence narratives. If a reimbursement pathway emerges for any subset of products (or for magistral preparations), regulators may ask for clearer articulation of:
Medical cannabis supply chains into Poland often involve cross-border procurement in EUR-denominated contracts, while dispensing economics occur in PLN. If a future reimbursement framework introduces:
…then FX volatility becomes a first-order pricing variable. Companies should model at least:
Even outside reimbursement, importers often face cost stacking that is easy to underestimate:
If reimbursement reform increases scrutiny on real-world utilization and safety outcomes, these “back office” costs become more visible to policymakers—making it harder to justify high patient prices without a coherent health-economic narrative.
Poland’s reimbursement rules historically interact with distribution economics (wholesalers, pharmacies) in structured ways. External legal analysis in 2025 noted that reform proposals also touch distribution aspects, including margins.
External link: https://rzmlaw.com/en/alerts/broad-amendment-to-the-reimbursement-act-distribution-aspects/
For medical cannabis businesses, pharmacy behavior is central because most patients access products through pharmacies. If reimbursement or partial reimbursement is introduced, the margin logic could shift incentives in ways that change:
Reimbursement reform tends to pull compliance obligations closer to the payer. Medical cannabis operators should plan for a future where the Ministry and NFZ expect stronger post-market governance.
Even when a product is supplied as a raw material used in magistral preparations, regulators may expect robust safety monitoring processes across the supply chain. Companies should ensure:
Poland’s URPL is the key authority on medicinal product oversight.
External link (official): https://www.gov.pl/web/urpl-en
In many reimbursement systems, listing can be lost if supply commitments are not met, or if data obligations are not fulfilled. Even in the absence of a current broad reimbursement channel for medical cannabis, a reform that introduces new categories or pilot pathways may bring with it:
Given Poland’s reliance on imports, companies should design “continuity by default” programs:
Your operational focus correctly highlights the possibility that reform could enable pilot programs or carve-outs specific to magistral preparations using cannabis raw material.
Why this is plausible:
What a pilot could require from industry:
Poland’s reimbursement reform discussions are moving quickly enough that businesses should prepare in parallel, not sequentially.
A reimbursement-ready dossier mindset helps even for non-reimbursed markets because it forces discipline:
At minimum, price for:
Include:
If prescriptions have been sensitive to policy constraints, physician adoption will also be sensitive to:
RWE programs don’t need to be massive to be useful. Start with:
If reimbursement reform increases transparency and reporting requirements, expect:
Patients and clinicians are watching the reimbursement debate closely because the core barrier remains affordability.
Key points:
Because the reform is evolving, the best compliance practice is to monitor primary sources and reputable regulatory analysis.
Start here:
The focus keyword for 2026 planning should be: Poland medical cannabis reimbursement 2025—not because reimbursement is guaranteed, but because the reform agenda will likely tighten expectations around pricing transparency, utilization reporting, and supply continuity. For manufacturers and importers, the winning strategy is to treat Poland as a market where payer-style evidence and compliance discipline are becoming central—even when most transactions remain cash-pay.
If you operate in Poland (or plan to), use https://cannabisregulations.ai/ to monitor regulatory updates, build reimbursement-ready compliance workflows, and pressure-test your licensing, import, pharmacovigilance, and pricing strategy against the next wave of reform.
